Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

ATLAS ACS trial in hot seat at FDA panel, mainly about missing data

SILVER SPRINGS, Md.The FDAs Cardiovascular and Renal Drugs Advisory Committee, in a May 23 meeting to assess new indications for rivaroxaban (Xarelto, Bayer HealthCare/Janssen Pharmaceuticals), kicked off with the ATLAS ACS trial investigators and sponsor addressing the FDAs trial concerns, specifically related to patient withdrawal from the trial and missing data.

Abiomed skips into black for FY12

Abiomed, a developer of heart support technologies, has reported a 25 percent increase in revenues, pushing the company into the black for the fiscal year (FY) 2012. The 2012 fourth quarter also saw double-digit revenues.

Lancet: Bad news for HDLs rep as the good cholesterol

Being genetically predisposed to higher concentrations of high-density lipoprotein (HDL) cholesterol provides no protective benefits against MI, according to a meta-analysis published online May 17 in Lancet. The results put in question whether drugs designed to raise HDL levels will succeed in reducing the risk of heart attacks.

HRS: Ablation superior to antiarrhythmic drugs as first-line therapy for AF

Pulmonary vein isolation with radiofrequency ablation is safe for patients with symptomatic atrial fibrillation (AF) and significantly superior to the current first-line therapy approach of antiarrhythmic drugs, according to trial results presented May 11 at the 33rd annual scientific sessions of the Heart Rhythm Society.

SCAI: Phoning the patient can lead to near-perfect DAPT adherence

LAS VEGASA simple, low-cost approach of four telephone contacts with patients following drug-eluting stent implantation significantly improves one-year drug adherence of dual antiplatelet therapy (DAPT) to near perfect scores, based on the findings of the single-center, Canadian EASY-IMPACT trial presented May 9 as a scientific poster at the 35th annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI).

Roche ditches dalcetrapib, due to disappointing trial results

After underwhelming results, Roche has pulled its second analysis of the dalcetrapib dal-OUTCOMES Phase III trial after the Data and Safety Monitoring Board pinpointed the trial's lack of clinically meaningful efficacy.

Lilly sees slight dip in Q1

Eli Lilly has reported a small decrease in net income and total revenue for the first quarter of 2012, compared with the first quarter of 2011.

Covidien reports strong growth in Q2

Covidien has reported double-digit net income results for the second quarter of fiscal 2012, which ended March 31.

Displaying 1673 - 1680 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.